ArticleTransboundary and emerging diseases2023
Investigating the Genetic Evolution of PCV2 and PCV3 across Six Swine Herds in China from 2020 to 2021.
Article in Transboundary and emerging diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- EZH2 enhances PCV2 replication through inhibition of MMP1 and MMP12 transcription activity.Veterinary research · 2026Article
- Epidemiological and genetic variation analysis of emerging porcine circovirus type 3 in Henan Province, 2023-2024.BMC veterinary research · 2026Article
- Epidemiological investigation of PCV2 and PCV3 in three provinces of Northeast China in 2025.BMC veterinary research · 2026Article
- Epidemiological Survey of Porcine Circovirus Types 2 and 3 in Liaoning Region of China and Preparation of Monoclonal Antibodies Against PCV3 Cap Protein.Veterinary sciences · 2026Article
- Investigating the Presence and Genetic Variability of Porcine Circovirus Types 2 and 3 in Live Markets in Border Cities of Northeast China.Transboundary and emerging diseases · 2025Article
- Porcine Circovirus Type 3: Diagnostics, Genotyping, and Challenges in Vaccine Development.Transboundary and emerging diseases · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To elucidate the prevalence, molecular evolution, and coinfection of PCV2 and PCV3 in China, we collected samples from six large-scale swine herds located in Heilongjiang, Henan, Hebei, and Hubei provinces and Xinjiang Uygur autonomous region from 2020 to 2021. Overall, 1,201 samples were analyzed and sequenced by PCR to identify the dominant genotypes of PCV2 and PCV3, and genetic variations in the capsid protein genes of PCV2 and PCV3 were evaluated. The major epidemic genotypes of PCV2 and PCV3 were different across different regions. The infection rate of PCV2 and PCV3 was 72.1% and 26.3%, respectively, and the coinfection rate was 18.6%. PCV2d was the dominant genotype across all herds. The PCV2d-positive rate in PCV2-positive samples was 93.5%-100% in five out of six herds, indicative of its predominance. PCV3 prevalence in China widely varied, and no dominant genotype was identified. Four, 21, 11, and 11 strains with PCV2a, PCV2d, PCV3a, and PCV3c genotypes were detected, respectively, with the capsid protein containing four, five, eight, and three aa sites with mutations, respectively. Overall, our findings revealed the dominant epidemic genotypes of PCV2 and PCV3 in six herds across five provinces in China, in addition to the main aa sites with mutations in the capsid protein. We believe that these results will facilitate the diagnosis, prevention, and control of PCV2 and PCV3 in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.